Several forms of stem cell modification are currently envisioned that will facilitate the development of the next generation of cell-based therapeutics. Integrating viral vectors are commonly used to permanently and most efficiently insert genes of interest, or to introduce libraries of genes to conduct screens. A current major research emphasis and area of expertise of investigators at CHOP is to characterize genetic disorders in stem cells. One of the next areas of high priority of research will be to develop methods to correct monogenic genetic disorders. For this purpose, ZFNs are currently the only method that has sufficient efficiency to modify stem cells at levels necessary to support therapy. We will be providing these services in a timely, cost-efficient manner that will provide high quality large-scale products that avoids the need for each investigator to develop the necessary skill sets. By providing the best state-of-the-art backbone for the vectors and the latest in ZFN technology we anticipate that we will not only allow better standardization of product on the UPENN/CHOP campus, but also enhance the quality of available products, leading to enhanced productivity and synergy on campus in the field of benign hematopoiesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK090969-04
Application #
8507225
Study Section
Special Emphasis Panel (ZDK1-GRB-G)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
4
Fiscal Year
2013
Total Cost
$167,889
Indirect Cost
$49,256
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Wunderlich, Mark; Brooks, Ryan A; Panchal, Rushi et al. (2014) OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood 123:e134-44
Sullivan, Spencer K; Mills, Jason A; Koukouritaki, Sevasti B et al. (2014) High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood 123:753-7
Kamat, Viraj; Paluru, Prasuna; Myint, Melissa et al. (2014) MicroRNA screen of human embryonic stem cell differentiation reveals miR-105 as an enhancer of megakaryopoiesis from adult CD34+ cells. Stem Cells 32:1337-46
Thom, Christopher S; Traxler, Elizabeth A; Khandros, Eugene et al. (2014) Trim58 degrades Dynein and regulates terminal erythropoiesis. Dev Cell 30:688-700
Paralkar, Vikram R; Mishra, Tejaswini; Luan, Jing et al. (2014) Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development. Blood 123:1927-37
Shin, Jae-Won; Buxboim, Amnon; Spinler, Kyle R et al. (2014) Contractile forces sustain and polarize hematopoiesis from stem and progenitor cells. Cell Stem Cell 14:81-93
Paluru, Prasuna; Hudock, Kristin M; Cheng, Xin et al. (2014) The negative impact of Wnt signaling on megakaryocyte and primitive erythroid progenitors derived from human embryonic stem cells. Stem Cell Res 12:441-51
Tiyaboonchai, Amita; Mac, Helen; Shamsedeen, Razveen et al. (2014) Utilization of the AAVS1 safe harbor locus for hematopoietic specific transgene expression and gene knockdown in human ES cells. Stem Cell Res 12:630-7
Crispino, John D; Weiss, Mitchell J (2014) Erythro-megakaryocytic transcription factors associated with hereditary anemia. Blood 123:3080-8
Buxboim, Amnon; Swift, Joe; Irianto, Jerome et al. (2014) Matrix elasticity regulates lamin-A,C phosphorylation and turnover with feedback to actomyosin. Curr Biol 24:1909-17

Showing the most recent 10 out of 21 publications